Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny bubbles of hydrogen and oxygen to be infused into humans for first time

NCT ID NCT07357909

Knowledge-focused Sponsor: Yayasan Inovasi Molekuler Indonesia (Indonesia Molecular Innovation Foundation) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This first-in-human study tests whether hydrogen-oxygen ultrafine bubbles can be safely infused into the bloodstream of healthy adults. About 40 participants will receive two infusions one week apart, with doses increasing in later groups. The study only checks for side effects and does not aim to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hydrogen-oxygen ultrafine bubbles
What this could lead to
If safe, this could pave the way for future studies exploring whether these bubbles have any medical uses.
What could go wrong
This is a very early, small safety study in healthy people. It is not designed to test if the bubbles help any disease, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 30 to 60 years at the time of enrollment. * Judged to be healthy or to have mild, stable, well-controlled medical conditions based on medical history, physical examination, vital signs, and screening laboratory assessments. * Body mass index (BMI) within 18.5 to 30.0 kg/m². * Able and willing to comply with all study procedures and scheduled visits. * Able to understand the study procedures and provide written informed consent prior to participation. Exclusion Criteria: * History or presence of clinically significant cardiovascular, pulmonary, neurological, hepatic, renal, hematologic, or immunologic disease that, in the investigator's judgment, could increase risk or interfere with study participation. * Known history of stroke, transient ischemic attack, myocardial infarction, heart failure, or significant arrhythmia. * Active infection, inflammatory condition, or febrile illness within 14 days prior to screening. * Abnormal baseline laboratory findings considered clinically significant by the investigator. * Known hypersensitivity or allergy to components of the investigational infusion or intravenous administration materials. * Current or recent (within 30 days) participation in another interventional clinical study. * Use of investigational drugs or therapies within 30 days prior to enrollment. * Pregnancy or breastfeeding. Women of childbearing potential who are unwilling to use effective contraception during the study period. * Any condition that, in the investigator's opinion, would make participation unsafe or compromise interpretation of study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy volunteer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ben Mari Hospital

    Malang, East Java, 60217, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.